For US Healthcare Professionals
Prescribing Information for All Merck Products

Request Samples


MDs, DOs, and other licencsed practioners (depending on state-level requirements) may request samples through MerckProductServices.

Sign In Register Now! 
You can sign in to MerckServices® using your MerckMedicus™ or MerckSource® user name and password.
User name:
Password:
Forgot your user name or password?
 
 Remember me
To request samples, you must sign in. You will then be taken to a list of samples that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form within the time frame specified. Once the Sample Request Form is validated, most sample requests are shipped within 3-5 business days.

To request complimentary samples, you must sign in. You will then be shown a list of the different complimentary sample formulations for that product that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must then be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form. You should receive the samples requested via UPS delivery within 14 business days of Merck receiving the completed form.

IMPORTANT PRODUCT INFORMATION


SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older.

SELECTED SAFETY INFORMATION

SINGULAIR should not be used as rescue medication to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.

Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.

While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.

Patients receiving SINGULAIR should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.

The most common adverse reactions with an incidence >5% and greater than placebo in controlled clinical trials were upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and otitis.

SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.

Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.

Before prescribing SINGULAIR, please read the Prescribing Information. The Patient Information also is available.

All product names listed on this site are registered trademarks owned by or licensed to a subsidiary of Merck & Co., Inc.
MerckProductServices, MerckServices, MerckSource, Merck OnCall, MerckMedicus, and MerckEngage are trademarks or registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.